Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group study

Australasian Radiology

Volumn 43, Issue 4, 1999, Pages 487-494

  Poulsen, M ^a,h   Denham, J ^b   Spry, N ^c   Lamb, D ^d   Peters, L ^e   Krawitz, H ^f   Penniment, M ^g   Williamson, S ^a   Tripcony, L ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c GEELONG HOSPITAL   (Australia)

^d WELLINGTON HOSPITAL   (New Zealand)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h Queensland Radium Institute   (Australia)

Author keywords

Accelerated fractionation; Cost; Head and neck cancer; Toxicity

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HEAD CANCER; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NECK CANCER; NOSE FEEDING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COSTS AND COST ANALYSIS; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 0032721423     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1673.1999.00718.x     Document Type: Article

References (14)

1. 1. Million R, Cassisi I. Management of Head and Neck Cancer. A Multidisciplinary Approach. JB Lippincott Company, Philadelphia, 1984.
2. 2. Horiot J. An overview of the EORTC hyperfractionation trials in head and neck cancer. Radiother Oncol 1996; 40: S30.
3. 3. Cummings B, Keane TJ, Pintilie M et al. A prospective randomised trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinoma of the larynx and pharynx. Radiother Oncol 1996; 40: S30.
4. 4. Peters LJ, Ang KK. Altered fractionation schemes. In: Mauch PM, Loeffler MD (eds) Radiation Oncology Technology and Biology. WB Saunders Co., Philadelphia, 1994; 545-65.
5. 5. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmer M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44: 123-36.
6. 6. Wang CC. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation schemes. Int J Radiat Oncol Biol Phys 1988; 14: 1143-6.
7. 7. Horiot J, Bontemps P, van de Bogaert W et al. Accelerated fractionation compared to conventional fractionation improves loco-regional control in radiotherapy of advanced head and neck cancers: Results of EORTC 22851 randomised trial. Radiother Oncol 1997; 44: 111-21.
8. 8. Ang K, Peters L, Weser R et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990; 19: 1339-45.
9. 9. Lamb D, Spry N, Gray A, Johnson A, Alexander S, Dally M. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother Oncol 1990; 18: 107-16.
10. 10. Lamb D, Denham J, Moruma P, Gray J. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II Study. Radiother Oncol 1998; 49: 29-32.
11. 11. Hamilton C, Poulsen M, Walker Q et al. Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Australas Radiol 1999; 43: 227-32.
12. 12. Dische S, Warburton M, Jones D, Lartigav E. The recording of morbidity related to radiotherapy. Radiother Oncol 1989; 16: 103-8.
13. 13. Denham J, Walker Q, Lamb D et al. Mucosal regeneration during radiotherapy. Radiother Oncol 1996; 41: 109-18.
14. 14. Overgaard J, Hansen H, Sapru W et al. Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomised multicentre study of 5 versus 6 fractions per week: preliminary report from DAHANCA 6 and 7 trial. Radiother Oncol 1996; 40: S31.